Clinical AI company Sensyne Health has signed a five-year non-exclusive Strategic Research Agreement (SRA) with Milton Keynes University Hospital NHS Foundation Trust (MKUH) to enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines.
Milton Keynes NHS Foundation Trust has around 550 beds, including day acute and neonatal beds and employs around 3,500 staff, providing a full range of acute hospital services and specialist services to the population of Milton Keynes and surrounding areas. All in-patient services and most outpatient services are provided on the main hospital site. the Trust is organised into four clinical divisions (medicine, surgery, women and children and core clinical) and a number of corporate directorates
The dataset covers 650,000 unique patient records, with 55,000 annual hospital admissions from a patient population of approximately 350,000 people. The new SRA with MKUH brings the combined total of anonymised data available for analysis by Sensyne to 4.5 million patients.
Oxford-headquartered Sensyne Health stated that the research will be undertaken to high standards of information governance and data security in accordance with NHS principles, the UK government code of practice and data protection legislation. All data supplied to Sensyne will be anonymised by MKUH beforehand and the provision of the data will operate under an agreed Data Processing Protocol (DPP) under MKUH ethical oversight. MKUH patient data sits securely in a data warehouse which will facilitate efficient data processing with Sensyne and enable immediate implementation.
MKUH will receive 1.4 million ordinary shares in Sensyne Health representing 1.1% of the existing issued share capital of the company. This brings the total share ownership held by NHS trusts in Sensyne to 10.86%. MKUH will also receive from Sensyne an investment of up to £250,000 a year over the five-year term of the contract for specific investments in information technology to enable the curation and analysis of data under the SRA. MKUH will also receive a royalty on revenues that are generated by Sensyne from the research undertaken under the SRA. The financial return MKUH receives from Sensyne will be reinvested back into the NHS to fund patient care. MKUH has entered into a lock-up agreement whereby it has agreed not to dispose of any shares for a period of two years from the date the shares are issued
MKUH joins existing SRAs the company has in place with Oxford University Hospitals NHS Foundation Trust, Chelsea & Westminster Hospitals NHS Foundation Trust, South Warwickshire NHS Foundation Trust, Wye Valley and George Eliot NHS Trusts.
Lord Drayson, chief executive of Sensyne Health, said: “We are delighted to be working with Milton Keynes in using anonymised patient data to improve patient care and accelerate the development of new medicines. SRAs are a fundamental part of Sensyne’s unique model – giving NHS trusts equity, funding and the ability to share in revenues. Growing our access to anonymised patient data is key to our strategy. This new non-exclusive SRA moves us closer to our target of over five million unique patient records in the current financial year.”
Date published: October 28, 2020